Literature DB >> 1710519

Induction of the paroxysmal nocturnal hemoglobinuria phenotype in normal human erythrocytes: effects of 2-aminoethylisothiouronium bromide on membrane proteins that regulate complement.

J L Ezzell1, L A Wilcox, N J Bernshaw, C J Parker.   

Abstract

To investigate the mechanism by which treatment of normal human erythrocytes with the sulfhydryl reagent 2-aminoethylisothiouronium bromide (AET) induces susceptibility to complement mediated lysis, the effects of AET on the structural and functional integrity of decay accelerating factor (DAF), membrane inhibitor of reactive lysis (MIRL), and complement receptor type 1 (CR1) were examined. Following treatment with AET, erythrocyte MIRL and CR1 were no longer recognized in situ by antibodies, and antibody binding to DAF was diminished by approximately 50%. These studies indicated that the structural integrity of the three complement regulatory proteins was either partially (DAF) or completely (MIRL and CR1) disrupted by AET. Subsequent experiments showed that functional inactivation paralleled the structural disruption. Treatment of normal erythrocytes with AET induced susceptibility to cobra venom factor-initiated hemolysis, indicating that the functional activity of MIRL had been destroyed. The capacity of erythrocyte CR1 to serve as a cofactor for factor I-mediated cleavage of iC3b to C3c and C3dg was lost following treatment with AET. C3 convertase activity increase markedly following treatment of erythrocytes with AET, but convertase activity on AET cells was approximately 50% less than that observed when DAF function on normal cells was completely inhibited by antibody. Susceptibility of AET cells to acidified serum lysis was shown to be due primarily to inactivation of MIRL. Unexpectedly, in acidified serum the activity of the amplification C3 convertase of the APC was found to be controlled by MIRL as well as by DAF. These studies show that AET induces susceptibility to complement-mediated lysis by disrupting the structural and functional integrity of membrane constituents that regulate the activity of both the C3 convertases and the membrane attack complex of complement.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1710519

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation.

Authors:  Markus J Harder; Nadine Kuhn; Hubert Schrezenmeier; Britta Höchsmann; Inge von Zabern; Christof Weinstock; Thomas Simmet; Daniel Ricklin; John D Lambris; Arne Skerra; Markus Anliker; Christoph Q Schmidt
Journal:  Blood       Date:  2016-12-27       Impact factor: 22.113

2.  Potential impact of complement regulator deficiencies on hemolytic reactions due to minor ABO-mismatched transfusions.

Authors:  Priyanka Pandey; Waseem Q Anani; Jerome L Gottschall; Gregory A Denomme
Journal:  Blood Adv       Date:  2017-10-11

3.  Structure of the CD59-encoding gene: further evidence of a relationship to murine lymphocyte antigen Ly-6 protein.

Authors:  J G Petranka; D E Fleenor; K Sykes; R E Kaufman; W F Rosse
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-01       Impact factor: 11.205

4.  Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients.

Authors:  Christoph Q Schmidt; Markus J Harder; Eva-Maria Nichols; Mario Hebecker; Markus Anliker; Britta Höchsmann; Thomas Simmet; Ádám I Csincsi; Barbara Uzonyi; Isabel Y Pappworth; Daniel Ricklin; John D Lambris; Hubert Schrezenmeier; Mihály Józsi; Kevin J Marchbank
Journal:  Immunobiology       Date:  2016-01-06       Impact factor: 3.144

5.  Comparative Analysis of Novel Complement-Targeted Inhibitors, MiniFH, and the Natural Regulators Factor H and Factor H-like Protein 1 Reveal Functional Determinants of Complement Regulation.

Authors:  Markus J Harder; Markus Anliker; Britta Höchsmann; Thomas Simmet; Markus Huber-Lang; Hubert Schrezenmeier; Daniel Ricklin; John D Lambris; Paul N Barlow; Christoph Q Schmidt
Journal:  J Immunol       Date:  2015-12-07       Impact factor: 5.422

6.  Rational engineering of a minimized immune inhibitor with unique triple-targeting properties.

Authors:  Christoph Q Schmidt; Hongjun Bai; Zhuoer Lin; Antonio M Risitano; Paul N Barlow; Daniel Ricklin; John D Lambris
Journal:  J Immunol       Date:  2013-04-24       Impact factor: 5.426

7.  Immune adherence-mediated opsonophagocytosis: the mechanism of Leishmania infection.

Authors:  M Domínguez; A Toraño
Journal:  J Exp Med       Date:  1999-01-04       Impact factor: 14.307

8.  Complement Evasion Mediated by Enhancement of Captured Factor H: Implications for Protection of Self-Surfaces from Complement.

Authors:  Andrew P Herbert; Elisavet Makou; Zhuo A Chen; Heather Kerr; Anna Richards; Juri Rappsilber; Paul N Barlow
Journal:  J Immunol       Date:  2015-10-12       Impact factor: 5.422

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.